Healthcare companies of Merck KGaA, Darmstadt, Germany

Reprint Fulfillment

The Lancet published the results for MANEUVER, a Phase 3 trial that evaluated PIMJETMI® (pimicotinib).

The citation for this publication is: Xu H et al. *Lancet.* 2026;407(10533):1072-1083.

This article is available via open access to interested stakeholders and can be downloaded via the MANEUVER publication hyperlink, or through *The Lancet.*

This reprint may include information that is not included in the Prescribing Information for PIMJETMI. Please click here for the FDA-approved Prescribing Information for PIMJETMI, which includes complete information regarding its approved use(s), contraindications, warnings and precautions, and other Important Safety Information.

© 2026 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.
PIMJETMI is a registered trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates.
US-PIMI-00137 11/26
EMD Serono, Inc. and SpringWorks Therapeutics, Inc. are healthcare companies of Merck KGaA, Darmstadt, Germany.